Results 91 to 100 of about 17,588 (197)

Determination of Topotecan by ELISA.

Biological and Pharmaceutical Bulletin, 2001
A highly sensitive ELISA for the determination of (s)-9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) capable of measuring as low as 80 pg/ml was developed. Anti-topotecan antibody was obtained by immunizing rabbits with topotecan conjugated with bovine serum albumin using diazotized m-aminobenzoic acid as a cross-linker.
SAITA, Tetsuya, FUJITO, Hiroshi, MORI, Masato   +2 more
openaire   +3 more sources

Mathematical models characterising the kinetics and dynamics of topotecan to account for drug resistance mechanisms [PDF]

This thesis describes the use of mathematical modelling in studying the kinetics and dynamics of the anti-cancer agent topotecan (TPT), a semi-synthetic derivative of the natural extract camptothecin (CPT), which has been found to act as an inhibitor ...
Atari, M. I. (Mohammed Isam)
core  

A review of topotecan in combination chemotherapy for advanced cervical cancer

, 2008
Minoo Robati, David Holtz, Charles J DuntonDepartment of Obstetrics and Gynecology, Main Line Gynecologic Oncology, Lankenau Hospital, Wynnewood, PA, USAAbstract: Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy and ...
David Holtz, Minoo Robati, Charles J Dunton   +2 more
core  

Intrathecal topotecan in adult patients with neoplastic meningitis

, 2010
PURPOSE: The efficacy and safety of intrathecal topotecan were assessed in patients with neoplastic meningitis (NM) by retrospective chart review. SUMMARY: Fourteen patients (median age, 57 years) with NM were treated with the standard of care (i.e ...
Gammon, David C., Bhatt, Mansi S., Van Horn, Alexis, Benvenuti, Matthew, Tran, Lan, Glantz, Michael J.   +5 more
core   +1 more source

Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models

Neoplasia: An International Journal for Oncology Research, 2005
To investigate the cellular/molecular basis of the activity of a novel lipophilic camptothecin, gimatecan (ST1481), against slowly proliferating cells, we performed a comparative study of topotecan and gimatecan in human bladder cancer models (HT1376 and
Paola Ulivi, Wainer Zoli, Francesco Fabbri, Giovanni Brigliadori, Luca Ricotti, Anna Tesei, Marco Rosetti, Michelandrea De Cesare, Giovanni L. Beretta, Elisabetta Corna, Rosanna Supino, Franco Zunino   +11 more
doaj   +1 more source

Topotecan uptake and efflux in topotecan resistant cancer cells

, 2000
喜樹鹼能抑制第一型拓蹼異構酵素，在實驗室中可抑制癌細胞生長。Topotecan及CPT-11 是兩個喜樹鹼的衍生物，最近已 開發成功。Topotecan 可治療卵巢癌而CPT-11 可治療大腸癌。目前二者都使用在各種癌症的臨床試驗，以尋求更廣泛的適 應症。以喜樹鹼置於癌細胞生長培養液中，往往產生對所有喜樹鹼衍生物的抗藥性。進一步分析可發現，抗藥性癌細胞中，第一型拓蹼異構酵素可能會下降或是產生突變，以致對喜樹鹼抑制劑的敏感度下降。我們先前發現，以第二型拓蹼異構酵素抑制劑mitoxantrone ...
楊志新
core  

Novobiocin Sensitizes Bcrp/Mxr/Abcp Overexpressing Topotecan-Resistant Human Breast Carcinoma Cells to Topotecan and Mitoxantrone

, 2009
Background : Novobiocin was shown to sensitize cancer cells to etoposide and alkylating agents. Human breast carcinoma cells exposed to topotecan ( MCF7/TPT-300 cells) developed resistance to both mitoxantrone and topotecan.
YANG, CHIH-HSIN;CHEN, YAO-CHANG;KUO, MIN-LIANG, 楊志新;陳耀昌;郭明良   +1 more
core  

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment

Diagnostics
Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor, and overall survival (OS) remains poor despite intensive efforts to develop new treatment strategies.
Laura Lambrecht, Paola Arnold, Jürgen Behr, Pontus Mertsch, Amanda Tufman, Diego Kauffmann-Guerrero   +5 more
doaj   +1 more source

Response to carboplatin +/− topotecan-containing ophthalmic artery chemosurgery (OAC).

, 2013
Representative case. Left: Reese-Ellsworth Group VB (IC D) left eye prior to treatment Right: Same eye following three OAC cycles consisting of carboplatin and topotecan. Note dramatic response of tumors following carboplatin/topotecan therapy.
Brian P. Marr (307426), David H. Abramson (307429), Jasmine H. Francis (307427), Scott E. Brodie (307428), Gowtham Jonna (448809), Y. Pierre Gobin (307424), Ira J. Dunkel (307425)   +6 more
core   +1 more source

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

OncoImmunology, 2018
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life.
S. Faraj, M. Bahri, S. Fougeray, A. El Roz, J. Fleurence, J. Véziers, M. D. Leclair, E. Thébaud, F. Paris, S. Birklé   +9 more
doaj   +1 more source